文献速递甲状腺核医学肿瘤 PET/CT

[68Ga]Ga-Trivehexin PET/CT 在甲状旁腺功能亢进症中的新型显像方法

A novel imaging approach in hyperparathyroidism: [68Ga]Ga-Trivehexin PET/CT.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-06-03

该回顾性研究纳入38例生化确诊的原发性甲状旁腺功能亢进症(PHPT)患者,比较[68Ga]Ga-Trivehexin PET/CT与[99mTc]Tc-MIBI SPECT/CT的定位效能。患者层面检出率分别为92%与74%,病灶层面为98%与58%(P<0.05),且双时间点显像无显著增益,早期采集似已足够。

要点

  • [68Ga]Ga-Trivehexin PET/CT病灶检出率98%,显著高于MIBI的58%
  • 患者层面检出率92% vs 74%,多腺体及亚厘米病灶优势明显
  • 早期显像(约40分钟)已足够,延迟显像无显著附加价值

核心结论

  • [68Ga]Ga-Trivehexin PET/CT对PHPT功能亢进甲状旁腺组织的定位检出率高于MIBI显像。

研究设计与样本

  • 回顾性研究,38例生化确诊PHPT患者均行MIBI显像与[68Ga]Ga-Trivehexin PET/CT,比较患者层面与病灶层面检出率。

主要发现

  • 患者层面MIBI与[68Ga]Ga-Trivehexin PET/CT正确检出分别为28/38(74%)与35/38(92%)。
  • 病灶层面[68Ga]Ga-Trivehexin PET/CT检出49/50(98%),MIBI检出29/50(58%)(P<0.05)。
  • [68Ga]Ga-Trivehexin PET/CT在18个MIBI阴性或不确定病灶中显示明确局灶摄取。
  • 双时间点显像早、延迟扫描病灶SUVmax及病灶-本底比无显著差异。
  • 动态显像显示病灶对比度快速上升后达平台,约25分钟后无一致改善。

关键数值与推荐

  • 患者层面检出率:MIBI 28/38(74%),[68Ga]Ga-Trivehexin PET/CT 35/38(92%)。
  • 病灶层面检出率:MIBI 29/50(58%),[68Ga]Ga-Trivehexin PET/CT 49/50(98%),P<0.05。
  • 早期显像于注射后约40±20分钟采集,延迟显像于80±20分钟,3例行动态显像。

临床怎么用

  • 对PHPT患者,尤其多腺体或亚厘米病灶、MIBI阴性或不确定者,可考虑[68Ga]Ga-Trivehexin PET/CT定位。
  • 早期约40分钟采集即可满足诊断,无需常规延迟显像。

局限性

  • 回顾性研究设计,样本量有限(38例患者、50个病灶),动态显像仅3例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the diagnostic performance of [68Ga]Ga-Trivehexin PET/CT for localizing hyperfunctioning parathyroid tissue in patients with primary hyperparathyroidism (PHPT) and to compare it with [99mTc]Tc-MIBI scintigraphy with SPECT/CT (MIBI scan). METHODS: In this retrospective study, patients with biochemically confirmed PHPT underwent both MIBI scan and [68Ga]Ga-Trivehexin PET/CT. Patient- and lesion-based detection rates were compared between modalities. [68Ga]Ga-Trivehexin PET/CT was acquired at approximately 40 ± 20 min after injection; delayed imaging at 80 ± 20 min was performed in a subset. Dynamic PET imaging was performed in three patients. Quantitative parameters, including SUVmax and lesion-to-background ratios, were recorded. Clinically relevant subgroups, including MEN-1-associated PHPT and persistent disease after surgery, were assessed. RESULTS: A total of 50 parathyroid-related lesions were evaluated in 38 patients. On patient-based analysis, MIBI scan and [68Ga]Ga-Trivehexin PET/CT correctly localized hyperfunctioning parathyroid tissue in 28 of 38 (74%) and 35 of 38 (92%) patients, respectively. On lesion-based analysis, [68Ga]Ga-Trivehexin PET/CT detected 49 of 50 lesions (98%), compared with 29 of 50 lesions (58%) detected by MIBI scan (P < 0.05). [68Ga]Ga-Trivehexin PET/CT demonstrated distinct focal uptake in 18 lesions with negative or equivocal MIBI findings. Dual-time-point imaging showed no significant differences in lesion SUVmax or lesion-to-background ratios between early and delayed scans. Dynamic imaging demonstrated a rapid increase in lesion contrast followed by a plateau, with no consistent improvement beyond approximately 25 min. CONCLUSION: [68Ga]Ga-Trivehexin PET/CT demonstrated higher detection rates than MIBI scan for localizing hyperfunctioning parathyroid tissue in PHPT, particularly in multiglandular and subcentimetric disease. Early acquisition appears sufficient, with limited added value of delayed imaging.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Denizmen Zorba D, Kuyumcu S, Has Simsek D, et al. A novel imaging approach in hyperparathyroidism: [68Ga]Ga-Trivehexin PET/CT. Eur J Nucl Med Mol Imaging. 2026. PMID: 42234003. doi:10.1007/s00259-026-07965-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。